Cite
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
MLA
van Kruchten, Michel, et al. “Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer.” Cancer Discovery, vol. 5, no. 1, Jan. 2015, pp. 72–81. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-14-0697.
APA
van Kruchten, M., de Vries, E. G., Glaudemans, A. W., van Lanschot, M. C., van Faassen, M., Kema, I. P., Brown, M., Schröder, C. P., de Vries, E. F., & Hospers, G. A. (2015). Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discovery, 5(1), 72–81. https://doi.org/10.1158/2159-8290.CD-14-0697
Chicago
van Kruchten, Michel, Elisabeth G de Vries, Andor W Glaudemans, Meta C van Lanschot, Martijn van Faassen, Ido P Kema, Myles Brown, Carolien P Schröder, Erik F de Vries, and Geke A Hospers. 2015. “Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer.” Cancer Discovery 5 (1): 72–81. doi:10.1158/2159-8290.CD-14-0697.